Branded Legacy Inc. Unveils Cutting-Edge GMP Facility to Accelerate Life-Saving Inhaled Naloxone Development
Branded Legacy (OTC: BLEG) has unveiled a new 22,000-square-foot GMP facility in Vancouver, Canada, dedicated to developing innovative inhaled naloxone devices for opioid overdose treatment. The state-of-the-art facility features advanced ISO Class 7 & 8 cleanrooms, high-containment capabilities, and integrated laboratory systems.
The facility represents a significant milestone following BLEG's acquisition of BioLegacy Evaluative Group and partnerships with McMaster University and Stanford University. Led by CEO Amin Janmohamed and Executive Chair Dr. Kristian Thorlund, the company aims to accelerate the development of affordable overdose-reversal solutions while maintaining potential for future expansion into vaccine delivery and other medications.
Branded Legacy (OTC: BLEG) ha inaugurato un nuovo impianto GMP di 22.000 metri quadrati a Vancouver, in Canada, dedicato allo sviluppo di innovativi dispositivi inalatori di naloxone per il trattamento delle overdose da oppioidi. L’impianto all’avanguardia è dotato di camere bianche ISO Classe 7 e 8, capacità di contenimento elevate e sistemi di laboratorio integrati.
La struttura rappresenta una tappa significativa dopo l’acquisizione da parte di BLEG del BioLegacy Evaluative Group e delle partnership con McMaster University e Stanford University. Guidata dal CEO Amin Janmohamed e dal Presidente Esecutivo Dr. Kristian Thorlund, l’azienda intende accelerare lo sviluppo di soluzioni economiche per l’inversione delle overdose, mantenendo al contempo il potenziale di future espansioni nella somministrazione di vaccini e di altri farmaci.
Branded Legacy (OTC: BLEG) ha inaugurado una nueva instalación GMP de 22.000 metros cuadrados en Vancouver, Canadá, dedicada al desarrollo de innovadores dispositivos inhalados de naloxona para el tratamiento de sobredosis por opioides. La instalación de vanguardia cuenta con salas limpias ISO Clase 7 y 8, capacidades de contención altas y sistemas integrados de laboratorio.
La instalación representa un hito significativo tras la adquisición por parte de BLEG del BioLegacy Evaluative Group y de asociaciones con la Universidad McMaster y la Universidad de Stanford. Liderada por el CEO Amin Janmohamed y el presidente ejecutivo Dr. Kristian Thorlund, la empresa busca acelerar el desarrollo de soluciones asequibles para revertir sobredosis, manteniendo el potencial de futuras expansiones hacia la entrega de vacunas y otros medicamentos.
브랜디드 레거시(OTC: BLEG)가 캐나다 밴쿠버에 22,000제곱피트 규모의 GMP 시설를 새롭게 개설했습니다. 이 시설은 오피오이드 과다복용 치료를 위한 혁신적인 흡입형 나록손 장치를 개발하는 데 전념합니다. 이 최첨단 시설은 ISO Class 7 및 8의 클린룸, 고위험 격리 능력 및 통합 실험실 시스템을 갖추고 있습니다.
이 시설은 BLEG가 BioLegacy Evaluative Group를 인수하고 맥마스터 대학교와 스탠포드 대학교와의 파트너십을 맺은 뒤 중요한 이정표를 나타냅니다. CEO Amin Janmohamed와 실행 의장 Dr. Kristian Thorlund의 주도로, 이 회사는 저렴한 가격의 과다복용 해소 솔루션 개발을 가속하고 백신 전달 및 다른 약물에 대한 향후 확장 가능성도 유지하고자 합니다.
Branded Legacy (OTC: BLEG) a dévoilé une nouvelle installation GMP de 22 000 pieds carrés à Vancouver, Canada, dédiée au développement de dispositifs inhalés de naloxone innovants pour le traitement des overdoses aux opioïdes. Cette installation à la pointe de la technologie dispose de chambres propres ISO classe 7 et 8, de capacités de confinement élevées et de systèmes de laboratoire intégrés.
L’installation représente une étape importante à la suite de l’acquisition par BLEG du BioLegacy Evaluative Group et des partenariats avec l’Université McMaster et l’Université de Stanford. Dirigée par le PDG Amin Janmohamed et le président exécutif Dr. Kristian Thorlund, l’entreprise vise à accélérer le développement de solutions abordables pour inverser les overdoses tout en conservant le potentiel d’une expansion future vers la délivrance de vaccins et d’autres médicaments.
Branded Legacy (OTC: BLEG) hat eine neue GMP-Anlage mit 22.000 Quadratfuß in Vancouver, Kanada, vorgestellt, die der Entwicklung innovativer inhalierbarer Naloxon-Geräte zur Behandlung von Opioid-Überdosierungen gewidmet ist. Die hochmoderne Einrichtung verfügt über ISO-Klassen-7 und -8 Reinräume, Hochschutzkapazitäten und integrierte Laborsysteme.
Die Anlage stellt einen bedeutenden Meilenstein dar, nachdem BLEG das BioLegacy Evaluative Group erworben hat und Partnerschaften mit McMaster University und Stanford University eingegangen sind. Unter der Leitung von CEO Amin Janmohamed und dem Executive Chair Dr. Kristian Thorlund strebt das Unternehmen danach, die Entwicklung erschwinglicher Überdosierungs-Lösungen zu beschleunigen, während das Potenzial für künftige Erweiterungen in der Impfstoffabgabe und anderen Medikamenten erhalten bleibt.
Branded Legacy (OTC: BLEG) كشفت عن منشأة GMP جديدة مساحتها 22,000 قدم مربع في فانكوفر، كندا، مخصصة لتطوير أجهزة Naloxone استنشاقية مبتكرة لعلاج حالات جرعة زائدة من المواد الأفيونية. تتميز المنشأة المتقدمة بغرف نظيفة من ISO Class 7 و8، وقدرات احتواء عالية، وأنظمة مختبر متكاملة.
تمثل المنشأة علامة فارقة بعد استحواذ BLEG على BioLegacy Evaluative Group وشراكات مع جامعة ماكماستر وجامعة ستانفورد. بقيادة الرئيس التنفيذي أمين جانموهاد والرئيس التنفيذي للمجلس الدكتور كريستيان ثورلاند، تهدف الشركة إلى تسريع تطوير حلول سريعة ورخيصة لعكس حالات الجرعة الزائدة مع الحفاظ على إمكانية التوسع مستقبلاً في توصيل اللقاحات وأدوية أخرى.
Branded Legacy (OTC: BLEG) 已在加拿大温哥华揭幕一座新的 22,000 平方英尺 GMP 设施，专注于开发用于阿片类药物过量治疗的创新吸入式纳洛酮装置。该先进设施拥有 ISO Class 7 与 8 的洁净室、高水平生物防护能力，以及集成实验室系统。
该设施是在 BLEG 收购 BioLegacy Evaluative Group 并与 麦克马斯特大学和斯坦福大学 建立伙伴关系之后实现的一个重要里程碑。由首席执行官 Amin Janmohamed 与执行董事长 Dr. Kristian Thorlund 领导，该公司旨在加速开发可负担的过量逆转解决方案，同时保留未来扩展到疫苗递送及其他药物的潜力。
- New 22,000-square-foot GMP facility enhances manufacturing capabilities and regulatory compliance
- Strategic partnerships with McMaster University and Stanford University strengthen R&D capabilities
- Facility's versatile infrastructure supports future pipeline expansion beyond naloxone into vaccines and other medications
- Advanced cleanroom facilities ensure high-quality production with strict particle control standards
- Significant capital investment in new facility may impact short-term financial position
- Operating costs likely to increase with new facility maintenance and operations
BioLegacy's New Vancouver Hub Drives Innovation in Opioid Crisis Solutions with Unmatched Manufacturing and Research Capabilities
VANCOUVER, British Columbia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- via IBN – BioLegacy Evaluative Group, Inc., a wholly-owned subsidiary of Branded Legacy Inc. (OTC: BLEG) and an emerging leader in life sciences innovation, proudly announces the official opening of its state-of-the-art 22,000-square-foot Good Manufacturing Practice (GMP) facility in Vancouver, Canada. This milestone, following the recent acquisition of the facility, establishes BLEG as a leader in developing innovative, low-cost inhaled naloxone devices to combat the escalating opioid overdose crisis.
The new facility serves as BioLegacy's central hub for research, development, and production, building on Branded Legacy's strategic acquisition of BioLegacy Evaluative Group and partnerships with McMaster University and Stanford University's Dr. Eran Bendavid. These collaborations, combined with the facility's advanced infrastructure, enable BLEG to accelerate the development of safe, effective, and accessible overdose-reversal solutions.
"Our new facility is the foundation for BioLegacy's mission to deliver affordable, accessible overdose-reversal solutions at scale," said CEO Amin Janmohamed. "By combining academic partnerships with state-of-the-art infrastructure, we are uniquely positioned to translate scientific breakthroughs into life-saving products."
Facility Highlights
- State-of-the-Art GMP Facility – Built to global pharmaceutical standards, ensuring scalability and long-term value.
- Advanced ISO Class 7 & 8 Cleanrooms – Engineered for superior, compliant production across diverse product lines, maintaining strict particle limits (=352,000 particles/m³ =0.5 µm, =83,200 =1 µm, and =2,930 =5 µm in ISO 7 spaces) to ensure exceptional quality.
- High-Containment Capabilities: Equipped to safely handle potent, hazardous, and controlled substances manufacturing.
- Integrated Laboratory Systems: In-house testing and validation streamline development and reduce costs.
- Regulatory Expertise: On-site teams with Health Canada and FDA experience facilitate smooth product approvals.
Dr. Kristian Thorlund, Executive Chair of BLEG, emphasized, "Dealing with the opioid epidemic means bringing devices and products to the populations using extremely hazardous materials. It is imperative that the products we develop can be used safely to both counter-act hazardous materials and work to minimize harms associated with them. These new facilities open up an enormous scientific capability for us."
A virtual tour led by Dr. Thorlund, showcasing the facility's advanced capabilities, is now available for stakeholders at https://youtu.be/pTNw2PxE2fU
Strategic Impact
The facility, dedicated initially to BioLegacy's inhaled naloxone program, enhances the company's patented intranasal naloxone delivery device, improving accessibility and dosing precision for opioid overdose treatment. Its versatile infrastructure also supports future pipeline expansion, including nasal delivery of vaccines and other medications, opening opportunities in global markets for rapid pandemic response and improved access in underserved regions.
About BioLegacy Evaluative Group, Inc.
BioLegacy Evaluative Group Inc. is a life sciences company dedicated to developing innovative therapies and devices addressing urgent global health challenges. With strategic partnerships at McMaster University and Stanford University, and a newly acquired GMP-compliant manufacturing facility, BLEG is positioned to deliver scalable, cost-effective solutions in areas of high unmet need.
About Branded Legacy, Inc.
Branded Legacy, Inc. (OTC: BLEG) is a holdings company focused on health and wellness, developing innovative solutions to combat addiction by preventing overdoses and supporting recovery. Through its subsidiary, BioLegacy Evaluative Group, and strategic partnerships with McMaster University and Stanford University, Branded Legacy leverages cutting-edge research and advanced manufacturing to deliver transformative healthcare solutions.
Investor Relations:
Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.
FAQ
What is the size and location of Branded Legacy's new GMP facility?
What are the main features of BLEG's new Vancouver facility?
Who are Branded Legacy's key research partners for the naloxone development program?
What is the primary focus of BLEG's new Vancouver facility?
What are the future expansion plans for Branded Legacy's Vancouver facility?
